×
Back to Agenda
Session 4 Track 2: Optimizing Oligonucleotide Therapeutics: Translating PK/PD and Tissue Half-Life into Smarter Dose Selection and Risk Assessment
Session Chair(s)
Tod Harper, PHD
Scientific Associate Director
Amgen, United States
Representative Invited
FDA, United States
Session 4 Track 2: Optimizing Oligonucleotide Therapeutics: Translating PK/PD and Tissue Half-Life into Smarter Dose Selection and Risk Assessment
Speaker(s)
Translational PK/PD Modeling Considerations
Representative Invited
GlaxoSmithKline, United Kingdom
Role of Tissue Half Life in Designing Clinical Studies
Representative Invited
Stoke Therapeutics, United States
Nonclinical Dose Selection, Safety Margins, and Translational Strategies for Oligonucleotide-based Therapeutics: Results from an IQ DruSafe ONT Working Group Cross-Industry Survey
Tod Harper, PHD
Amgen, United States
Scientific Associate Director
Have an account?